The main purpose of this study is to determine the risks and benefits of ceritinib (ZYKADIA)
given in combination with trametinib (MEKINIST) in patients who have progressed on prior
Ceritinib that has been approved for patients with metastatic non-small cell lung cancer
(NSCLC) by the US Food and Drug Administration (FDA). While ceritinib is not currently
FDA-approved specifically in melanoma, researchers believe ceritinib may also help keep
melanoma cancer cells from growing and therefore potentially help patients with melanoma as
well. Trametinib is currently FDA-approved for melanoma with a BRAFV600-mutation.
If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.